Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Tarsus Pharmaceuticals, Inc. (TARS) reported a Q3 loss of $0.61 per share, which is better than the Zacks Consensus Estimate of a $0.90 loss. This is an improvement from the $1.28 loss per share reported a year ago.
November 13, 2024 | 11:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tarsus Pharmaceuticals reported a Q3 loss of $0.61 per share, beating the Zacks Consensus Estimate of a $0.90 loss. This marks an improvement from the previous year's $1.28 loss per share.
The better-than-expected earnings report is likely to have a positive short-term impact on Tarsus Pharmaceuticals' stock price. The improvement from last year's loss also suggests positive momentum.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100